Search

Your search keyword '"Dermatologic agents -- Product development"' showing total 622 results
Start Over Descriptor "Dermatologic agents -- Product development"
622 results on '"Dermatologic agents -- Product development"'

201. Novartis reveals new data from Phase III Cosentyx study

Subjects
Novartis AG -- Product development, Pharmaceutical industry -- Product development, Secukinumab, Psoriasis, Medical research, Dermatologic agents -- Product development, Chemistry, Cosentyx (Medication)
Abstract

M2 PHARMA-March 6, 2019-Novartis reveals new data from Phase III Cosentyx study (C)2019 M2 COMMUNICATIONS Switzerland-based Novartis has revealed new data for 441 Chinese patients with moderate to severe plaque [...]

Published
2019

202. Novartis reveals new data from Phase III Cosentyx study

Subjects
Novartis AG -- Product development, Pharmaceutical industry -- Product development, Secukinumab, Psoriasis, Medical research, Dermatologic agents -- Product development, Business, Cosentyx (Medication)
Abstract

M2 EQUITYBITES-March 6, 2019-Novartis reveals new data from Phase III Cosentyx study (C)2019 M2 COMMUNICATIONS http://www.m2.com Switzerland-based Novartis has revealed new data for 441 Chinese patients with moderate to severe [...]

Published
2019

203. Treating minor injuries, bruises, and skin irritations

Author

Lowery, Mark

Subjects
Hyland's Inc. -- Product development, Medline Industries Inc. (Mundelein, Illinois) -- Product development, Medical test kit industry -- Product development, Rash (Dermatology) -- Care and treatment, Medical equipment and supplies industry -- Product development, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Business, Pharmaceuticals and cosmetics industries
Abstract

The summer months can be a time of increased activity for many people, as warmer temperatures usher in numerous outdoor events that can be more strenuous and bring us closer [...]

Published
2016

204. Lipidor Updates on Positive Clinical Phase I/II Data in Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Arts and entertainment industries
Abstract

Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of [...]

Published
2013

205. CSIR SCIENTISTS TO DEVELOP NEW SKIN CANCER DRUG (develop a synthetic transcription factor composed of peptide molecule)

Subjects
Skin cancer -- Drug therapy, Antineoplastic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Scientists, Peptides, Antimitotic agents -- Product development, Banking, finance and accounting industries, Business, Business, international, News, opinion and commentary
Abstract

The scientists at the Council of Scientific and Industrial Research (CSIR), Hyderabad, have found a new drug to treat rare form of skin cancer melanoma. At present the scientists have [...]

Published
2013

207. BIOCON MEETS CLINICAL TRIAL MILESTONE FOR PSORIASIS DRUG (by meeting the primary and secondary goals of clinical trials for 'itolizumab' conducted on 200 patients over 52 weeks)

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business, Business, international, News, opinion and commentary
Abstract

Biocon of Bangalore is making efforts to bring out its affordable drug 'itolizumab', which is used for the treatment of psoriasis. It has met the primary and secondary goals of [...]

Published
2012

208. Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis

Subjects
Clinical trials, Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Oct 31, 2017 (GLOBE NEWSWIRE via COMTEX) -- - Top-line data expected by Q2 2018 - Samumed, LLC, today announces the enrollment of the first psoriasis patient in [...]

Published
2017

209. MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis

Subjects
Clinical trials, Bacteria, Staphylococcal infections -- Drug therapy, Atopic dermatitis -- Drug therapy, Therapeutics -- Product development, Dermatologic agents -- Product development, Skin, Advertising executives, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug 21, 2017 (GLOBE NEWSWIRE via COMTEX) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the [...]

Published
2017

210. University to Commence Medicinal Herbs Clinical Trial

Subjects
Biological diversity conservation, Dermatology -- Formulae, receipts, prescriptions, Medicine, Botanic, Clinical trials, Dermatologic agents -- Product development, Medicinal plants -- Product development, Medicine, Herbal, Universities and colleges, News, opinion and commentary
Abstract

Byline: Yohanes Jemaneh Apr 06, 2017 (The Ethiopian Herald/All Africa Global Media) -- Debre Birhan University announced that it has finalized preparations to commence clinical trial on four medicinal herbs. [...]

Published
2017

212. Janssen Pharmaceutical's psoriasis drug achieves primary endpoint in phase 3 trial

Subjects
Novartis AG -- Product development, Pharmaceutical industry -- Product development, Psoriasis -- Drug therapy, Dermatologic agents -- Product development, Interleukins, Medical research, Chemistry, Cosentyx (Medication), Tremfya (Medication)
Abstract

Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate [...]

Published
2018

213. Janssen Pharmaceutical's psoriasis drug achieves primary endpoint in phase 3 trial

Subjects
Novartis AG -- Product development, Pharmaceutical industry -- Product development, Psoriasis -- Drug therapy, Dermatologic agents -- Product development, Interleukins, Medical research, Business, Cosentyx (Medication), Tremfya (Medication)
Abstract

Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate [...]

Published
2018

214. Avillion Opens IND for Phase 2 Study of Anti-IL-17 A/F Nanobody for treatment of Psoriasis

Subjects
Merck & Company Inc. -- Product development, High technology industry, Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-February 20, 2018-Avillion Opens IND for Phase 2 Study of Anti-IL-17 A/F Nanobody for treatment of Psoriasis (C)2018 M2 COMMUNICATIONS - London, UK-based drug development company Avillion LLP has [...]

Published
2018

215. RISANKIZUMAB: ABBVIE/BOEHRINGER INGELHEIM, PHASE III

Author

Agier, Anita

Subjects
Johnson & Johnson -- Product development, Credit Suisse Group AG -- Product development, Psoriasis, Respiratory agents, Financial services industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Financial services industry, Business, Health care industry, Stelara (Medication) -- Product development
Abstract

Indication: Plaque psoriasis What the clinical trials found: Risankizumab, which has orphan designation in Crohn's disease, is in P3 trials in a variety of indications, including Psoriasis, Ankylosing spondylitis, Crohn's [...]

Published
2017

216. Dermal Clinical Evaluation Society: Annual Educational Seminar VII, September 14, 1990

Author

Jass, Herman E.

Subjects
Dermatologic agents -- Product development, Dermatology -- Conferences, meetings and seminars, Cosmetics -- Product development, Business, Pharmaceuticals and cosmetics industries
Abstract

Presenting an educational seminar is not an easy task for a highly specialized society like the Dermal Clinical Evaluation Society (DCES). Because many members do not spend most of their [...]

Published
1990

217. A stable w/o/w multiple emulsion

Author

De Luca, M., Grossiord, J.L., Medard, J.M., Vaution, C., and Seiller, M.

Subjects
Cosmetics -- Product development, Dermatologic agents -- Product development, Emulsions -- Methods, Business, Pharmaceuticals and cosmetics industries
Abstract

Multiple emulsions (Figure 1) can be considered controlled-release delivery systems. The possibility of encapsulating and delivering to the skin active substances provides many interesting opportunities, not only for the pharmacist [...]

Published
1990

218. Cosmetics love liposomes!

Author

Franklin, Betty

Subjects
Cosmetics industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Liposomes -- Usage, Dermatologic agents -- Product development, Health
Published
1990

219. Dyax Jumps on Positive Drug News; The company's new drug DX-88 showed it helps treat the hereditary skin disease angioedema

Subjects
DX-88 (Medication) -- Product development, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Securities, Angioneurotic edema -- Care and treatment, Angioneurotic edema -- Drug therapy, Dermatologic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Company securities, Dyax Corp. -- Product development, Dyax Corp. -- Securities
Published
2007

220. Selected dermatologic disorders

Author

Kaufman, Michele

Subjects
Infectious skin diseases -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Care and treatment, Product development
Abstract

Selected dermatologic disorders New Drugs Product type/proposed indication ACTINIC KERATOSIS T4 endonuclease V topical liposome-encapsulated T4 endonu- (Dimericine) clease V enzyme/prevention of actinic AGI Dermatics keratosis in patients with xeroderma [...]

Published
2005

221. Zovirax formulation proves superior

Subjects
GlaxoSmithKline Consumer Healthcare Ltd. -- Product development, Dermatologic agents -- Product development, Cold sores -- Drug therapy, Herpes simplex -- Drug therapy, Pharmaceutical industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Zovirax (Medication)
Abstract

Zovirax delivers up to five times more aciclovir to the skin than other OTC cold sore creams, according to a paper published in a pharmaceutical journal. The superiority of the [...]

Published
2005

222. OTC: New prescription product: Biatain Rectangular

Subjects
Coloplast Corp. -- Product development, Coloplast Corp. -- Marketing, Bandages and bandaging -- Marketing, Bandages and bandaging -- Product development, Dermatologic agents -- Product development, Dermatologic agents -- Marketing, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Marketing, Wounds and injuries -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Dermatology -- Marketing, Company marketing practices, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Dressing - non-adhesive 10cmx20cm and adhesive 18x28cm For the treatment of irregular-shaped exuding wounds at the granulation or epithelialisation stage of healing, such as leg ulcers, pressures sores and diabetic [...]

Published
2005

223. Counselling point: Unguentum M

Subjects
Crookes Healthcare Ltd. -- Product development, Pharmaceutical industry -- Product development, Eczema -- Drug therapy, Dermatologic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Unguentum M (Medication)
Abstract

Q: My child suffers from eczema, so I am using creams to keep her skin moisturised at all times. I am looking for an effective product that is still not [...]

Published
2005

224. Face product aims for happy days

Author

Brookman, Faye

Subjects
Dermatologic agents -- Product development, Dermatologic agents -- Advertising, Dermatologic agents -- Distribution, Cosmetics industry -- Distribution, Cosmetics industry -- Advertising, Cosmetics industry -- Product development, Company distribution practices, Business, Fashion, accessories and textiles industries, Retail industry
Abstract

NEW YORK -- When Anson Williams was starring as Potsie on 'Happy Days' in the late Seventies, the show's creator, Garry Marshall, recommended actors wear a few hats to compensate [...]

Published
2004

225. New drugs

Subjects
MGI Pharma Inc. -- Product introduction, Alcon Laboratories Inc. -- Product development, Doak Dermatologics -- Product introduction, Aloxi (Medication) -- Product introduction, CiproDex Otic (Medication) -- Product development, Dermatologic agents -- Product development, Acne rosacea -- Care and treatment, Ophthalmic drugs -- Product development, Acute otitis media -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Product introduction, Antiemetics -- Product introduction
Abstract

Aloxi (palonosetron hydrochloride) injection, from MGI Pharma, Minneapolis, (952) 346-4700, has received FDA approval, at a dose of 0.25 mg, for the prevention of acute nausea and vomiting associated with [...]

Published
2003

227. Second drug approved for improving photoaged skin. (Rx Care)

Author

LoBuono, Charlotte

Subjects
Renova AB -- Product development, Ortho Dermatological -- Product development, Avage (Medication) -- Product development, Allergan (Medication) -- Product development, Pharmaceutical industry -- Product development, Dermatologic agents -- Product development
Abstract

Patients wishing to improve the appearance of skin that has aged prematurely after years of sun exposure now have another option. The Food & Drug Administration recently approved tazarotene (Avage, [...]

Published
2003

228. Skin infection

Subjects
Dermatologic agents -- Product development, Dermatologic agents -- Dosage and administration, Linezolid -- Product development, Linezolid -- Dosage and administration, Pharmaceutical industry -- Product development, Staphylococcus aureus infections -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Dermatology -- Dosage and administration, Health, Pharmaceuticals and cosmetics industries
Abstract

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Sponsored by GlaxoSmithKline. The purpose of this study is to provide further evidence of the clinical and [...]

Published
2010

229. Much ado about ageing: questions about a laboratory assay are making Sirtris, a high-profile biotechnology company, the talking point of the ageing field. Heidi Ledford investigates

Author

Ledford, Heidi

Subjects
Aging -- Drug therapy, Biotechnology industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Konrad Howitz wasn't looking for a fountain of youth. As director of biochemistry at BIOMOL International in Plymouth Meeting, Pennsylvania, Howitz wanted to add new molecular assays to the company's [...]

Published
2010

230. A study to evaluate the safety and efficacy of AZX100 drug product following excision of keloid scars

Subjects
Dermatologic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Keloids -- Drug therapy, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Capstone Therapeutics. The purpose of this study is to determine the safety of AZX100 Drug Product and to determine whether it is effective in preventing or reducing re-growth [...]

Published
2009

231. ZD1839 (Iressa) for recurrent or metastatic squamous cell carcinoma of the skin

Subjects
Squamous cell carcinoma -- Drug therapy, Antimitotic agents -- Product development, Antineoplastic agents -- Product development, Dermatologic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by MD Anderson Cancer Center; AstraZeneza. The primary objective of this study is as follows: 1) to explore the activity of ZD1839 administered to patients with SCC of the [...]

Published
2009

232. Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA

Subjects
Can-Fite BioPharma Ltd. -- Product development, Clinical trials, Dermatologic agents -- Product development, Psoriasis, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Otezla (Medication)
Abstract

- Phase III clinical study designed to establish Piclidenoson is superior to placebo as primary endpoint and non-inferior to Otezla at week 32 as secondary endpoint - Global psoriasis market [...]

Published
2016

233. Vyome Biosciences Administers First In-human Dose of VB 1953 in U.S. Phase 1 Clinical Study in Patients with Facial Acne Vulgaris

Subjects
Therapeutics Inc. -- Product development, Clinical trials, Acne -- Care and treatment, Dermatologic agents -- Product development, Medical research, Skin, Business, Business, international
Abstract

NEW DELHI -- Vyome Biosciences , a clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that it administered the first in-human [...]

Published
2016

234. BIOCAD Biotechnology Company Announces the Start of Phase 2 Clinical Trials of an Innovative Drug to Treat Severe Psoriasis

Subjects
Clinical trials, Biotechnology, Monoclonal antibodies, Dermatologic agents -- Product development, Biotechnology industries -- Product development, Psoriasis -- Drug therapy, Biological products -- Product development, Business, Business, international
Abstract

SAINT PETERSBURG, Russia -- BCD-085 is an innovative drug containing a humanized monoclonal anti-interleukin-17 (anti-IL17) antibody as an active ingredient. The primary objective of the international multicenter double-blind placebo-controlled study [...]

Published
2016

235. Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial

Subjects
Can-Fite BioPharma Ltd. -- Intellectual property -- Product development, Clinical trials, Patents, Dermatologic agents -- Product development, Psoriasis, Pharmaceutical industry -- Intellectual property -- Product development, Drug approval, Patent/copyright issue, Business, News, opinion and commentary
Abstract

- 2.4 million Europeans living with moderate-to-severe psoriasis - Global psoriasis market projected to reach $13.3 billion by 2024 PETACH TIKVA, Israel, Sept. 13, 2016 /PRNewswire/ -- http://www.can-fite.com/ . (NYSE [...]

Published
2016

236. New drug clears psoriasis in patients in long-term trials

Subjects
Protein binding, Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Biological products -- Product development, General interest, News, opinion and commentary, Northwestern University
Abstract

Byline: STEPHEN FELLER CHICAGO, June 10 (UPI) -- A decade ago, researchers thought there was no way to clear psoriasis, however a new drug has been seen in several clinical [...]

Published
2016

237. Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea

Subjects
Clinical trials, Skin diseases, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

REHOVOT, Israel and BRIDGEWATER, May 03, 2016 (GLOBE NEWSWIRE via COMTEX) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ('Foamix Pharmaceuticals'), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary [...]

Published
2016

238. Injectable eczema drug dupilumab effective in trials

Subjects
Regeneron Pharmaceuticals Inc. -- Product development, Sanofi S.A. -- Product development, Eczema -- Drug therapy, Atopic dermatitis -- Drug therapy, Skin care, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Byline: STEPHEN FELLER WASHINGTON, April 1 (UPI) -- A new drug to treat moderate to severe eczema nearly or completely cleared skin lesions in patients during two recent clinical trials, [...]

Published
2016

239. Can-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on March 7, 2016

Subjects
Can-Fite BioPharma Ltd. -- Forecasts and trends -- Product development, Dermatologic agents -- Product development, Psoriasis, Pharmaceutical industry -- Forecasts and trends -- Product development, Market trend/market analysis, Business, News, opinion and commentary
Abstract

Phase III psoriasis study expected to commence in 2016 PETACH TIKVA, Israel, March 3, 2016 /PRNewswire/ -- http://www.can-fite.com/ . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of [...]

Published
2016

240. Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape 2016-2018 - Research and Markets

Subjects
Dermatologic agents -- Product development, Psoriasis, Business, Business, international
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/fsdvq8/severe) has announced the addition of the 'Severe Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016' report to their offering. Severe Psoriasis - [...]

Published
2016

241. Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape 2016-2018

Subjects
Dermatologic agents -- Product development, Psoriasis, General interest, News, opinion and commentary
Abstract

Feb 12, 2016 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/t5sgrx/severe) has announced the addition of the 'Severe Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016' report [...]

Published
2016

243. Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated with Ziarco's Lead Compound ZPL-389

Subjects
Clinical trials, Dermatologic agents -- Product development, Psoriasis, Business, Business, international
Abstract

DISCOVERY PARK, Sandwich, United Kingdom -- Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, today announced that dosing has started in [...]

Published
2016

244. SCHERING AG

Subjects
Bayer HealthCare Pharmaceuticals -- Mergers, acquisitions and divestments -- Product development, Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments -- Product development, Pesticides industry -- Mergers, acquisitions and divestments -- Product development, Herbicides -- Mergers, acquisitions and divestments -- Product development, Dermatology -- Formulae, receipts, prescriptions, Drugs -- Product development, Dermatologic agents -- Product development, Chemical industry -- Mergers, acquisitions and divestments -- Product development, Chemicals -- Product development, Pharmaceutical industry -- Mergers, acquisitions and divestments -- Product development, Company acquisition/merger, Business, Chemicals, plastics and rubber industries, ABT-281 (Medication) -- Product development
Abstract

SCHERING AG has acquired worldwide rights to further develop and market the compound ABT-281 for atopic dermatitis and all other potential dermatological diseases from Abbott Laboratories. ABT-281 is a non-steroidal, [...]

Published
2001

245. High-Potency 'C' Product Introduced

Subjects
Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Dermatologic agents -- Product development, Health, Care and treatment, Product development
Abstract

Just 2 years after the development and successful introduction of its premier vitamin C skin care formulation, Dermatologic Cosmetic Laboratories (DCL) has developed a new, higher potency 'C' Scape Serum. [...]

Published
2001

246. Generics Pact

Subjects
Atrix Laboratories Inc. -- Product development, Geneva Pharmaceuticals Inc. -- Product development, Pharmaceutical industry -- Product development, Dermatologic agents -- Product development, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

BROOMFIELD, Colo. -- Atrix Laboratories Inc. and Geneva Pharmaceuticals Inc. have signed a pact for the development and manufacture of generic dermatology [...]

Published
2000

247. Geneva Pharmaceuticals

Subjects
Atrix Laboratories Inc. -- Contracts -- Product development, Sandoz Inc. -- Contracts -- Product development, Novartis AG -- Contracts -- Product development, Medical research, Medicine, Experimental, Pesticides industry -- Product development -- Contracts, Herbicides -- Product development -- Contracts, Dermatology -- Formulae, receipts, prescriptions, Drugs -- Product development, Dermatologic agents -- Product development, Chemical industry -- Product development -- Contracts, Chemicals -- Product development, Pharmaceutical industry -- Product development -- Contracts, Contract agreement, Business, Chemicals, plastics and rubber industries
Abstract

GENEVA Pharmaceuticals, the generics arm of Novartis AG, and Atrix Laboratories have signed a broad ten-year collaborative agreement to develop and manufacture prescription generic dermatology products. The alliance has a [...]

Published
2000

248. Youthglow's All-In- One Solution

Subjects
Youthglow -- Product development, Youthglow Activating Liposome Complex (Skin cream) -- Product development, Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Business, Pharmaceuticals and cosmetics industries, Care and treatment, Product development
Abstract

Youthglow's Activating Liposome Complex boasts the benefits of multiple skin-care products in one solution. This water-based liquid solution's active ingredient is beta glucan, which supports the skin's own antioxidant activity [...]

Published
2000

249. NIVEA(r) Skintellect

Subjects
Dermatologic agents -- Product development, Toiletries industry -- Product development, Nivea France -- Product development
Abstract

Science made simple. A guide to Nivea's breakthrough products that are revolutionizing the art of beautiful skin. People trust Nivea. It's the world's #1 name in skin care because the […]

Published
1999

250. In clinical trial, cream reduces squamous cell carcinoma risk

Subjects
Clinical trials, Skin creams -- Product development, Cancer prevention, Veterans, Skin cancer -- Prevention -- Risk factors, Dermatologic agents -- Product development, Toiletries industry -- Product development, Skin, Squamous cell carcinoma -- Prevention -- Risk factors, Health, Health care industry
Abstract

2018 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results